Protagonist Therapeutics
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of moderate-to-severe plaque psoriasis. Developed through a high-stakes collaboration between Protagonist Therapeutics (Nasdaq: PTGX) and Johnson & Johnson (NYSE: JNJ), the approval